Cardiovascular disease (CVD) is recognised as one of the major causes of morbidity and mortality globally. The progression of CVD is affected by a multitude of genetic, metabolic, and lifestyle-related factors. Among the various risk factors, lipoprotein(a) [Lp(a)], and Apolipoprotein B (ApoB) have recently been recognised for their pivotal role in the development of atherosclerosis, or the accumulation of plaques within the arterial walls. Knowledge of these biomarkers is essential not only for healthcare professionals managing patients with risk factors but also for patients, as it helps them make informed decisions regarding the prevention & management of CVD.
Conventional laboratory analysis, although highly accurate, requires venous blood sampling, sophisticated equipment & time-consuming procedures that can pose significant barriers to accessibility, especially in resource-poor settings. Point-of-care testing (POCT), as represented by the TSTBio iProtin analyser, overcomes these limitations by enabling rapid, accurate & painless assessment of major cardiovascular biomarkers.
What is Lipoprotein(a) and Why Is It Important?
Lipoprotein(a) is a type of cholesterol particle that has special characteristics:
It is involved in the formation of arterial plaques.
It is mainly genetically determined.
High levels of Lp(a) are associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD).
Educational Insights:
- Lp(a) testing can reveal who is at risk early on.
- Lp(a) is not affected by lifestyle, so standard cholesterol testing may not reveal this risk factor.
- Current international guidelines suggest that at least one measurement should be made during a lifetime.
Medical research has shown that patients with high Lp(a) will benefit from early treatment, such as lifestyle advice and lipid-lowering agents.
What is ApoB and Its Role in Cardiovascular Health?
Apolipoprotein B (ApoB) is a structural protein found in LDL and other atherogenic lipoproteins.
High ApoB means there are more cholesterol particles in the blood.
ApoB is a measure of metabolic cardiovascular risk.
Testing for Lp(a) and ApoB together gives a complete risk profile.
Studies have found that ApoB can be a better predictor of cardiovascular events than LDL cholesterol alone, making it an important marker.
Point-of-Care Testing: How Does iProtin Work?
iProtin is a point-of-care testing device that is intended to provide lab-quality results quickly.
Key Features:
- The device can test for Lp(a), ApoB, and CRP using a single finger-prick blood sample.
- Results can be obtained in less than 3 minutes.
- The device requires minimal preparation, and there is no need for centrifugation.
- The device is compact and portable and can be used in a clinic or in a remote area.
The testing procedure can be used for frequent monitoring and early detection of cardiovascular risk markers, which is important for patients in remote areas.
Clinical Validation of iProtin
A comparative study evaluated iProtin against two standard lab assays: Randox (Abbott Alinity c) and Roche (Cobas c502).
Findings:
- iProtin vs Randox: iProtin = 1.15 × Randox + 7.28 nmol/L (R²=0.906)
- iProtin vs Roche: iProtin = 1.02 × Roche + 17.54 nmol/L (R²=0.912)
- Randox vs Roche correlation: R²=0.973
Reliability:
- Inter-assay coefficient of variation (CV) over 5 days: 6.2–15.5%
- Intra-assay CV for repeated measurements: 13.2–14.3%
- Interpretation: iProtin shows strong agreement with laboratory tests, supporting its use for clinical monitoring and patient education.
How Biomarker Results Inform Clinical Decisions
Lp(a) Levels:
- Normal: <30 mg/dL
- Elevated: >30 mg/dL
ApoB Levels:
- Male: 46–174 mg/dL
- Female: 46–142 mg/dL
CRP Levels:
- Normal: <1 mg/dL
- Elevated: >1 mg/dL
Healthcare professionals use these values to:
- Stratify cardiovascular risk.
- Guide early interventions.
- Track response to therapies or lifestyle changes.
Note: Patients with high Lp(a) should discuss risk-reducing strategies with their physician, even if other cholesterol measures are normal.
Why Point-of-Care Testing Matters for Education and Awareness
Point-of-care technologies such as iProtin have a very educational role to play:
Enhanced Understanding of Cardiovascular Risk
Biomarkers can be used to help patients understand their individual risk.
Accessible Screening
Makes screening possible in clinics, community centers, and rural settings.
Timely Feedback
Quick results encourage informed discussions between patients and healthcare providers.
Support for Preventive Medicine
Early detection allows clinicians to implement lifestyle and treatment strategies sooner.
Enhanced Patient Engagement
Patients are more likely to follow recommendations when they understand their biomarker levels.
Evidence-Based Benefits of Lp(a) Testing
- Detects inherited cardiovascular risk not captured by standard cholesterol tests.
- Facilitates individualised treatment plans.
- Supports public health initiatives for early detection.
- Contributes to research and understanding of ASCVD progression.
Peer-reviewed studies confirm that routine Lp(a) testing can reduce long-term cardiovascular events by identifying high-risk individuals.
FAQs
1. Why is Lp(a) testing significant?
Lp(a) testing helps identify a genetic risk factor for atherosclerotic cardiovascular disease that may not be identified by standard cholesterol testing. High levels of Lp(a) are a risk factor for the development of plaque within the arteries. Early identification of high levels gives patients and physicians the opportunity to take preventive measures.
2. Can iProtin testing replace laboratory testing?
No. While iProtin testing is a valid point-of-care test, it should not be used to replace full laboratory testing. The purpose of iProtin testing is to assist with regular monitoring and early detection.
3. How is the iProtin sample collected?
The process of collecting the sample is quite easy and non-invasive. Only a drop of blood (5 μL) is required. This is sufficient, and there is no need for venous blood sampling.
4. What is the turnaround time for results?
The results are provided in less than 3 minutes. This is quite rapid and allows the doctor to discuss the results with the patient immediately. This is very helpful in reducing the waiting time of the patient and makes it easy for them to monitor their levels regularly.
5. Who will benefit from point-of-care testing?
Point-of-care testing is beneficial for patients who are at risk of cardiovascular disease, patients who require frequent monitoring, and patients who live in areas where access to the laboratory is difficult. It is also beneficial for healthcare professionals, as it enables them to make informed decisions quickly.
6. How do levels of ApoB affect risk assessment?
Higher levels of ApoB are associated with a higher number of atherogenic lipoproteins in the blood. This is a measure of metabolic cardiovascular risk and is used to identify patients who are at risk of developing plaque. ApoB testing, in combination with Lp(a), provides a complete risk profile for cardiovascular disease.
7. Is testing useful for patient education?
Yes. Point-of-care testing enables patients to see the actual values of the biomarkers, which helps them understand their cardiovascular risk. Patients are able to see the actual values, which makes the risk more real, and it motivates them to take an active role in managing their own health.
Conclusion:
Point-of-care testing for cardiovascular biomarkers is more than just convenience. It is a means of education, awareness, and informed decision-making.
TSTBio iProtin has excellent analytical performance, meets laboratory standards, and helps patients and healthcare professionals understand ASCVD risk. By providing accessible, rapid, and non-invasive testing, technologies such as iProtin improve public and patient education about cardiovascular health. Early detection of Lp(a), ApoB, and CRP enables empowered preventive measures.
POC Diagnostics illustrates the role of point-of-care technology in advancing medical knowledge while emphasising health education over commercialisation.